Business
Enovis Announces First Quarter 2026 Results
First-quarter sales growth of 5% on a reported basisFirst-quarter Reconstructive sales grew 11% on a reported basisReiterating full-year 2026 revenue, adjusted EBITDA, adjusted EPS, and Free Cash Flow Conversion guidance Dallas, TX, May 07, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 3, 2026. The Company will host an investor c
About this update from Enovis Corporation
[{"type":"image","alt":"Enovis Corporation","displaySize":"","headline":null,"caption":"Enovis Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":73,"url":"https://media.zenfs.com/en/globenewswire.com/04c85b7575377030906937c34935ae92"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lm6mKaAoTpyr0iAMM_2GWQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMg--/https://media.zenfs.com/en/globenewswire.com/04c85b7575377030906937c34935ae92","width":300,"height":73},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/lm6mKaAoTpyr0iAMM_2GWQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMg--/https://media.zenfs.com/en/globenewswire.com/04c85b7575377030906937c34935ae92","width":300,"height":73}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"First-quarter sales growth of 5% on a reported basis","length":52,"tagName":"p"}]},{"val":[{"type":"text","content":"First-quarter Reconstructive sales grew 11% on a reported basis","length":63,"tagName":"p"}]},{"val":[{"type":"text","content":"Reiterating full-year 2026 revenue, adjusted EBITDA, adjusted EPS, and Free Cash Flow Conversion guidance","length":105,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":220,"olType":false},{"type":"text","content":"Dallas, TX, May 07, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 3, 2026. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.","length":356,"tagName":"p"},{"type":"text","content":"First Quarter 2026 Financial Results","length":36,"tagName":"p"},{"type":"text","content":"Enovis’ first-quarter net sales of $589 million grew 5% on a reported basis and 3% on an organic basis from the same quarter in 2025. First quarter results reflect continued execution in P&R and Recon, stable end markets, and encouraging momentum in new product introductions, offset by the impact of fewer selling days. Compared to the same quarter in 2025, net sales in Recon grew 11% on a reported basis and 6% on an organic basis, and P&R was flat on a reported basis and 1% on an organic basis.","length":507,"tagName":"p"},{"type":"text","content":"Enovis also reported first-quarter net loss of $8 million...